Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: Implications for program replication

American Journal of Drug and Alcohol Abuse

Volumn 38, Issue 3, 2012, Pages 206-212

  Bruce, R Douglas ^a   Eiserman, Julie ^a   Acosta, Angela ^a   Gote, Ceilia ^b   Lim, Joseph K ^c   Altice, Frederick L ^a  

^a YALE UNIVERSITY   (United States)

^b South Central Rehabilitation Center   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis C treatment; Methadone

Indexed keywords

METHADONE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PATIENT COMPLIANCE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SELF CARE;

ADULT; ANTIVIRAL AGENTS; DIRECTLY OBSERVED THERAPY; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SELF ADMINISTRATION; VIRAL LOAD;

EID: 84859697923     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.643975     Document Type: Article

References (27)

1. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47(RR-19):1-39.
2. CDC. Hepatitis C. MMWR Morb Mortal Wkly Rep 2002; 51(RR-7):64-66.
3. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341(8):556-562.
4. Altice F, Bruce RD. Hepatitis C virus infection in United States correctional institutions. Curr Hepat Rep 2004; 3:112-118.
5. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug Alcohol Depend 2002; 67(2):117-123.
6. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29(3):159-165.
7. McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: Prevalence and public policy implications. J Addict Dis 2001; 20(1):19-31.
8. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: Knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001; 61(3):211-215.
9. Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schonbucher P, Bertisch B, Meili D, Renner EL. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: An open-label randomized multicenter trial. Infection 2005; 33(1):25-29.
10. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33(3):126-133.
11. Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for nontreatment of hepatitis C in veterans in care. J Viral Hepat 2005; 12(1):81-85.
12. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345(3): 215-217.
13. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40(1):120-124.
14. Harris KA, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010; 4(1):20-26.
15. Litwin AH, Harris KA, Jr, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, Kaswan D, Gourevitch MN, Arnsten JH. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2008; 37(1):32-40.
16. Martinez AD, Dimova R, Marks KM, Beeder AB, Zeremski M, Kreek MJ, Talal AH. Integrated internist-addiction medicine-hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat 2012; 19, 47-54.
17. Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication. Clin Infect Dis 2004; 38(Suppl. 5):S376-S387.
18. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial. Clin Infect Dis 2007; 45(6):770-778.
19. Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: A double-blind, placebo-controlled trial. Psychosomatics 2010; 51(5):401-408.
20. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J NervMent Dis 1980; 168(1):26-33.
21. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T,Westlake L. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 1992; 305(6846):160-164.
22. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: A model to improve engagement and outcomes. Int J Drug Policy 2007; 18(5):406-410.
23. Lertora JJ, Rege AB, Lacour JT, Ferencz N, George WJ, VanDyke RB, Agrawal KC, Hyslop Jr. NE. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991; 50(4):442-449.
24. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 2010; 38(4):338-345.
25. Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C -a new era in therapy. Aliment Pharmacol Ther, 2010; 32(1):14-28.
26. Castera L, Zigante F, Bastie A, Buffet C, Dhumeaux D, Hardy P. Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology 2002; 35(4): 978-979.
27. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36(5 Suppl. 1): S237-S244.